[go: up one dir, main page]

SI1572726T1 - 4-methylhexanoic kahalalide f compound - Google Patents

4-methylhexanoic kahalalide f compound

Info

Publication number
SI1572726T1
SI1572726T1 SI200331948T SI200331948T SI1572726T1 SI 1572726 T1 SI1572726 T1 SI 1572726T1 SI 200331948 T SI200331948 T SI 200331948T SI 200331948 T SI200331948 T SI 200331948T SI 1572726 T1 SI1572726 T1 SI 1572726T1
Authority
SI
Slovenia
Prior art keywords
kahalalide
methylhexanoic
compound
antitumoral
antiviral
Prior art date
Application number
SI200331948T
Other languages
Slovenian (sl)
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Manuel Aviles
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Priority claimed from EP03779140A external-priority patent/EP1572726B1/en
Publication of SI1572726T1 publication Critical patent/SI1572726T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
SI200331948T 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f compound SI1572726T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
EP03779140A EP1572726B1 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f compound
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
SI1572726T1 true SI1572726T1 (en) 2011-04-29

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331948T SI1572726T1 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f compound

Country Status (11)

Country Link
KR (2) KR101149095B1 (en)
AT (1) ATE490975T1 (en)
AU (1) AU2003285911B2 (en)
CY (1) CY1111319T1 (en)
DE (1) DE60335292D1 (en)
DK (1) DK1572726T3 (en)
IL (1) IL167724A (en)
NO (1) NO333448B1 (en)
PL (1) PL209129B1 (en)
PT (1) PT1572726E (en)
SI (1) SI1572726T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
ES2256305T3 (en) * 2000-10-31 2006-07-16 Pharma Mar, S.A. FORMULATIONS OF KAHALALIDE F.
EP1435990A1 (en) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
IL167724A (en) 2012-01-31
NO20052379L (en) 2005-07-15
NO20052379D0 (en) 2005-05-13
HK1082261A1 (en) 2006-06-02
DE60335292D1 (en) 2011-01-20
AU2003285911A1 (en) 2004-05-04
KR101149095B1 (en) 2012-05-30
PL377056A1 (en) 2006-01-23
DK1572726T3 (en) 2011-03-28
ATE490975T1 (en) 2010-12-15
AU2003285911B2 (en) 2009-11-19
KR20110114690A (en) 2011-10-19
PT1572726E (en) 2011-02-14
NO333448B1 (en) 2013-06-10
PL209129B1 (en) 2011-07-29
CY1111319T1 (en) 2015-08-05
KR20050070056A (en) 2005-07-05

Similar Documents

Publication Publication Date Title
MXPA04003796A (en) Substituted thioacetamides.
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
MXPA02011288A (en) Substituted thioacetamides.
GB0225474D0 (en) Therapeutic agents
MXPA05009682A (en) Methods of radiofluorination of biologically active vectors.
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
ZA200802848B (en) Potassium channel inhibitors
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
TW200701982A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
ATE486915T1 (en) AZEOTROP-LIKE COMPOSITION OF 1,2-DICHLORO-3,3,3-TRIFLUOROPROPENE AND HYDROGEN FLUORIDE
GB0216001D0 (en) Process and composition
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
MXPA02011039A (en) Fungicidal combinations of active agents.
IL157457A0 (en) Benzimidazoles that are useful in treating sexual dysfuction
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
ATE372330T1 (en) N-SULFONYLUREA APOPTOSIS PROMOTER
SI1572726T1 (en) 4-methylhexanoic kahalalide f compound
AU2001247241A1 (en) Biologically active analogs of discodermolide
MXPA05012605A (en) Compositions comprising gastrin compounds and their use in diabetes.
MX2008001548A (en) Antitumoral compounds.
ATE423780T1 (en) MACROCYCLES FOR THE TREATMENT OF CANCER DISEASES
IL142295A0 (en) Use of acylcarnitines as antitumour agents
LT2002131A (en) New use of fir oil for cosmetic
TW200607493A (en) Potassium channel inhibitors